Leukemia, stem cell transplant, cellular therapy, pharmacotherapy, dosing of medications in obesity, graft versus host disease, supportive care
Dr. Griffin is a Board Certified Oncology Pharmacist. He completed his PharmD at the UNC Eshelman School of Pharmacy and his residency training at UF Health Shands Hospital. Within the School of Pharmacy & Pharmaceutical Sciences, Griffin will develop and coordinate immunology courses for the second year of the PharmD curriculum. He joined UCI Health and the Chao Family Comprehensive Cancer Center to develop the role of and practice as an ambulatory pharmacist for the Hematopoietic Stem Cell Transplantation and Cellular Therapy Program.
Benitez LL, Perissinotti AJ, Rausch CR, Klaus J, Clark SM, Filtz M, Ratermann K, Treptow C, Griffin SP, Olson M, Crain M, Kadia T, Pettit K, Burke PW, Bixby DL, Marini BL. Multicenter comparison of high-dose cytarabine based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Leukemia & Lymphoma. 2021;Online ahead of print. doi: 10.1080/10428194.2021.1907378.
Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, Sweiss K, Griffin SP, Cahill K, Konig H, Esen A, Shergill A, Odenike O, Stock W, Quigley JG. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. American Journal of Hematology. 2020;95(8):937-43. doi: 10.1002/ajh.25838.
Chen F, Wu X, Niculite C, Gilca M, Petrusca D, Rogozea A, Rice S, Guo B, Griffin SP, Calin GA, Boswell HS, Konig H. Classic and targeted anti-leukaemic agents interfere with the cholesterol biogenesis metagene in acute myeloid leukaemia: Therapeutic implications. Journal of Cellular and Molecular Medicine. 2020;24(13):7378-92. doi: 10.1111/jcmm.15339.
Agrawal A, Ranganath P, Ervin KD, Schmidt CA, Cox EA, Nelson RP, Schwartz JE, Abu Zaid M, Abonour R, Robertson MJ, Brinda BJ, Griffin SP, Thakrar TC, Farag SS. Effect of Sirolimus levels between days 11 and 20 after allogeneic stem cell transplantation on the risk of hepatic sinusoidal obstruction syndrome. Bone Marrow Transplantation. 2020;Online ahead of print. doi: 10.1038/s41409-020-0987-1.
Hickey EL, Clemons B, Griffin SP, Cox J, Sutphin S, Ramlal R, Benitez L. Multi-center Evaluation of Arsenic Trioxide Dosing in Obese Patients with Low-Intermediate Risk Acute Promyelocytic Leukemia. Leukemia & Lymphoma. 2019;60(14):3557-60. doi: 10.1080/10428194.2019.1639163.
Griffin SP, Wheeler SE, Wiggins LE, Murthy HS, Hsu JW, Richards AI. Pharmacokinetic and Clinical Outcomes When Ideal Body Weight is Used to Dose Busulfan in Obese Hematopoietic Stem Cell Transplant Recipients. Bone Marrow Transplantation. 2019;54(2):218-225. doi: 10.1038/s41409-018-0240-3.
Griffin SP, Nelson JE. Impact of a Clinical Solid Organ Transplant Pharmacist on Tacrolimus Nephrotoxicity, Therapeutic Drug Monitoring, and Institutional Revenue Generation in Adult Kidney Transplant Recipients. Progress in Transplantation. 2016; 26(4):314-321. doi: 10.1177/1526924816667950.
American Society for Transplantation and Cellular Therapy
Hematology/Oncology Pharmacy Association